Filing Details

Accession Number:
0001415889-22-004082
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-04-15 16:02:15
Reporting Period:
2022-04-13
Accepted Time:
2022-04-15 16:02:15
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1070081 Ptc Therapeutics Inc. PTCT Pharmaceutical Preparations (2834) 043416587
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1578852 Elliott Mark Boulding C/O Ptc Therapeutics, Inc.
100 Corporate Court
South Plainfield NJ 07080
Exec. Vp And Clo No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2022-04-13 2,276 $11.23 63,386 No 4 M Direct
Common Stock Disposition 2022-04-13 2,276 $45.17 61,110 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2022-04-13 2,276 $11.23 2,276 $11.23
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2027-01-02 No 4 M Direct
Reported Derivative Holdings
Sec. Name Sec. Type Price Date Expiration Date Amount Remaning Holdings Nature of Ownership
Common Stock Stock Option (Right to Buy) $51.00 2025-01-01 85,600 85,600 Direct
Common Stock Stock Option (Right to Buy) $30.86 2026-01-03 70,000 70,000 Direct
Common Stock Stock Option (Right to Buy) $33.02 2029-01-21 72,500 72,500 Direct
Common Stock Stock Option (Right to Buy) $33.02 2029-01-21 17,500 17,500 Direct
Common Stock Stock Option (Right to Buy) $51.16 2030-01-28 59,500 59,500 Direct
Common Stock Stock Option (Right to Buy) $66.49 2031-01-05 59,500 59,500 Direct
Common Stock Stock Option (Right to Buy) $38.10 2032-01-06 54,000 54,000 Direct
Expiration Date Amount Remaning Holdings Nature of Ownership
2025-01-01 85,600 85,600 Direct
2026-01-03 70,000 70,000 Direct
2029-01-21 72,500 72,500 Direct
2029-01-21 17,500 17,500 Direct
2030-01-28 59,500 59,500 Direct
2031-01-05 59,500 59,500 Direct
2032-01-06 54,000 54,000 Direct
Footnotes
  1. This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on December 2, 2021.
  2. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $45.00 to $45.35 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
  3. Currently exercisable.
  4. This option was granted on January 22, 2019 and vests over four years, with 25% of the shares underlying the option vesting on January 22, 2020, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning April 22, 2020.
  5. This option was granted on January 22, 2019 and vests over four years, with 50% of the shares underlying the option vesting on January 22, 2022, and the remaining 50% of the original number of shares underlying the option vesting on January 22, 2023.
  6. This option was granted on January 29, 2020, and vests over four years, with 25% of the shares underlying the option vesting on January 29, 2021, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 29, 2021.
  7. This option was granted on January 6, 2021, and vests over four years, with 25% of the shares underlying the option vesting on January 6, 2022, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 6, 2022.
  8. This option was granted on January 7, 2022, and vests over four years, with 25% of the shares underlying the option vesting on January 7, 2023, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 7, 2023.